Julie Eastland Appointed CEO of Zentalis Pharmaceuticals to Lead Advancement of Azenosertib in Oncology

San Diego, CA, November 13, 2024 (Globe Newswire) -- Zentalis Pharmaceuticals has appointed Julie Eastland as CEO, supported by Ingmar Bruns, M.D., as Chief Medical Officer and Scott Myers as Chairperson of the Board, to strengthen its leadership. Julie Eastland has built an impressive career in the biotechnology and pharmaceutical industries, holding key leadership roles at Harpoon Therapeutics, where she served as CEO and led the company to its acquisition by Merck in 2024, Receptos, Inc., where she was CFO and CBO and played a pivotal role in its acquisition by Celgene, Amylin Pharmaceuticals, where she was Vice President of Corporate Development and Investor Relations, and Genoptix, where her leadership contributed to its acquisition by Novartis.

Read full article here.